These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
581 related articles for article (PubMed ID: 24974578)
1. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Brugos B; Sebestyen L; Tarr T; Vincze Z Pharmazie; 2014 Jun; 69(6):442-4. PubMed ID: 24974578 [TBL] [Abstract][Full Text] [Related]
2. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases. Shen K; Yu Y; Tang Z; Liu Z; Li L Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205 [TBL] [Abstract][Full Text] [Related]
3. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031 [TBL] [Abstract][Full Text] [Related]
4. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis]. Cai XY; Yang XY; Chen XH; Liang LQ; Guan MM; Qin SG; Fu JZ Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1436-9. PubMed ID: 15500738 [TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548 [TBL] [Abstract][Full Text] [Related]
6. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH; Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children. Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528 [TBL] [Abstract][Full Text] [Related]
8. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851 [TBL] [Abstract][Full Text] [Related]
9. [Laboratory and morphologic parameters in patients with lupus nephritis]. Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312 [TBL] [Abstract][Full Text] [Related]
10. Treatment and renal outcome of lupus nephritis: single center experience. Go KW; Teo SM Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517 [TBL] [Abstract][Full Text] [Related]
13. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. El-Sehemy MS; Al-Saaran AM; Baddour NM; Adam AG; Moez PE Egypt J Immunol; 2006; 13(1):39-52. PubMed ID: 17974149 [TBL] [Abstract][Full Text] [Related]
14. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Sjöwall C; Zickert A; Skogh T; Wetterö J; Gunnarsson I Arthritis Res Ther; 2009; 11(6):R188. PubMed ID: 20003354 [TBL] [Abstract][Full Text] [Related]
15. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470 [TBL] [Abstract][Full Text] [Related]
16. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132 [TBL] [Abstract][Full Text] [Related]
17. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989 [TBL] [Abstract][Full Text] [Related]